RxDoctor Payments Data

Anna Dodd

Family · Bandon, ORNPI 1023582673

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.3% of the total across 155 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 38.8% of the total. Reporting peaked in 2023 at $790 and has fallen 76.1% since, to $189 in 2025. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,567in general payments, 2019–2025

Across 155 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$997
  • Johnson & Johnson$534
  • E.r. Squibb & Sons, L.L.C.$291
  • Lilly USA, LLC$213
  • Galderma Laboratories, L.p.$159
  • Sanofi$133
  • plus $239 from 6 others

What the payments were for

  • Food & beverage$2,31990%
  • Education$24810%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,567 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$168,911
Medicare patients
765
Services billed
3,305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa19$378,398
Cosentyx Sensoready (2 Pens)Secukinumab12$86,506
Fluorouracil50$3,681
Clobetasol Propionate77$3,458
Metronidazole25$2,256
CiclopiroxCiclopirox Olamine95$2,033
Calcipotriene12$1,646
Triamcinolone Acetonide100$1,132
Ketoconazole73$1,031
Doxycycline Hyclate17$994
Betamethasone Dipropionate24$698
Mupirocin40$407
Ciclopirox34$263
Hydrocortisone29$196

Paid to pharmacies, not to this prescriber.

Other family in Bandon

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →